A Phase I, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of H008 (Carenoprazan Hydrochloride Tablets) in Healthy Volunteers
Latest Information Update: 20 Dec 2023
At a glance
- Drugs Keverprazan (Primary) ; Lansoprazole (Primary)
- Indications Duodenal ulcer; Erosive oesophagitis; Gastro-oesophageal reflux
- Focus Adverse reactions
- Sponsors Jiangsu Carephar Pharmaceutical
- 19 Sep 2022 Status changed from recruiting to completed, according to a Fosun Pharma USA.
- 24 Sep 2021 New trial record